Written By NeuLuna® Day & Night Cream - April 09 2024
Understanding and managing chronic skin conditions is critical to reduce their physical and psychological burden; in the case of more aggressive or visible conditions, such as head and neck dermatitis, research recommends earlier and more intense interventions for better patient outcomes.
Read more
Written By NeuLuna® Day & Night Cream - March 30 2024
Understanding the interconnection of our workout habits, skincare routines, and long-term health is a critical step in overall wellness. Exercising has both positive and negative outcomes for the skin, but with proper awareness and post-workout care, you don't need to let appearances get in the way of staying fit.
Read more
Written By NeuLuna® Day & Night Cream - March 22 2024
Affecting an estimated 3-10% of the population, seborrheic dermatitis is a chronic non-contagious skin condition, but treatment options remain limited in their efficacy, as compared to management protocols for other inflammatory skin diagnoses.
Read more
Written By NeuLuna® Day & Night Cream - March 15 2024
Psoriasis is one of the most common chronic inflammatory skin conditions, and it has been widely studied over the years, resulting in the development of effective treatments and management strategies. However, nail psoriasis is frequently overlooked, despite its significant disease burden, and there is notably less information available on the condition and treatment options.
Read more
Written By NeuLuna® Day & Night Cream - March 05 2024
Inflammatory skin conditions—such as atopic dermatitis, psoriasis and rosacea—affect an estimated 20-25% of the global population. As such, there are myriad treatment strategies to prevent inflammatory reactions in the skin; however, some of these methods may actually exacerbate other skin conditions, and should therefore be used with caution.
Read more
Written By NeuLuna® Day & Night Cream - February 27 2024
The study of our skin and the conditions that affect it is perpetually ongoing, with new discoveries and treatment methodologies coming to light every year. As such, the standardized guidelines for care must be regularly updated, particularly for conditions that affect significant percentages of the population and are being actively researched.
Read more
Written By NeuLuna® Day & Night Cream - February 20 2024
Between the ages of 12 and 24, it is estimated that 85% of people will experience acne in some form, making it one of the most common skin disorders. Even so, there remains a persistent and unfair social stigma against those with acne, in some cases making it harder for them to navigate the realms of employment, friendship or romance.
Read more
Written By NeuLuna® Day & Night Cream - February 14 2024
A new report published in the Journal of the American Academy of Dermatology suggests a connection between Irritable Bowel Disease (IBD) and rosacea. Basically, having IBD puts you at higher risk for rosacea, while having rosacea similarly increases your risk of IBD. This bidirectional association requires additional study for verification, but it offers new insight into the interconnectivity of systemic health conditions.
Read more
Written By NeuLuna® Day & Night Cream - February 06 2024
The uncomfortable experience of atopic dermatitis at any stage of life can be challenging, but young people, in particular, are more likely to experience bullying if they show symptoms of this common form of eczema. Fortunately, there are skincare interventions that can both prevent and treat flareups, reducing the likelihood of such unkind treatment from peers and the potential effects on mental health and self-image.
Read more
Written By NeuLuna® Day & Night Cream - January 31 2024
For the non-invasive treatment of various skin disorders and damage from excess sun exposure, Photodynamic therapy (PDT) is a reliable and convenient remedy. When combined with hyaluronic acid for moisturizing and rejuvenating our body's largest organ, this increasingly popular therapy can significantly improve the appearance of your skin.
Read more
